Ashvattha Therapeutics is leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines that selectively treat diseased cells only in regions of inflammation. By making precision medicine even more precise, our nanomedicine technology has the potential to change the standard of care across ophthalmology, neurology, inflammatory diseases and neuro-oncology.
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel nanomedicines enabled by our hydroxyl dendrimer (HD) technology to treat unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. Our HD platform builds therapeutics that are selectively taken up only by inflamed tissues, allowing us to treat diseases with unprecedented precision.
We have designed and optimized a nanomedicine that precisely targets reactive macrophages. microglia and retinal pigment epithelial cells (RPEs) after systemic administration
Our solution enables patient selection followed by treatment with anti-neuroinflammatory nanomedicine to target reactive microglia
OP-101 selectively targets pro-inflammatory macrophages and microglia responsible for excessive cytokine production
We are developing nanomedicines leveraging our ability to target tumor associated macrophages (TAMs)
– The study will evaluate the safety, tolerability and ability of [18F]OP-801 to cross the blood brain barrier and selectively target neuroinflammation in individuals with
REDWOOD CITY, Calif., February 2, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class
REDWOOD CITY, Calif., January 3, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class